+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are evaluating the drug WS016 in adults with hyperkalemia, a condition characterized by elevated potassium levels in the blood. This Phase 3 clinical trial aims to study the effectiveness and safety of WS016 through a two-part design including a corrective phase to quickly reduce potassium levels and a maintenance phase to keep potassium normal. An open-label extension phase is also included to assess longer-term treatment effects. In Part A, participants are first randomized to receive either oral WS016 12g or placebo three times daily for 48 hours during the corrective phase. Those who achieve normal potassium levels are then re-randomized to receive WS016 at doses of 6g, 12g, or 18g, or placebo once daily for 28 days in the maintenance phase. Part B is an open-label extension lasting 11 months, where participants receive WS016 starting at 12g daily, with dose adjustments based on potassium levels. Participants will have regular blood tests to monitor serum potassium and other health measures throughout the study. Researchers will track potassium levels during the maintenance phase and corrective phase to assess drug effects. Safety and tolerability will be monitored, and participants completing or discontinuing the maintenance phase may continue treatment in the extension phase. Overall participation can last up to nearly a year depending on enrollment in Part B.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are investigating treatments for metastatic pancreatic ductal adenocarcinoma mPDAC in this randomized, double-blind, placebo-controlled, multicenter phase III clinical trial. The study aims to compare overall survival between patients receiving a combination of TQB2868 injection, anlotinib hydrochloride capsules, and chemotherapy versus those receiving placebo combined with chemotherapy. This trial evaluates whether adding TQB2868, a dual antibody targeting PD-L1 and TGF-beta, to standard treatment may impact survival outcomes in patients with advanced pancreatic cancer. Participants are randomly assigned to one of two groups. The experimental group receives TQB2868 injection plus anlotinib hydrochloride capsules combined with gemcitabine hydrochloride injection and paclitaxel for injection. The control group receives a placebo injection combined with anlotinib hydrochloride capsules and the same chemotherapy drugs. Treatments are given as first-line therapy for metastatic disease, with dosing and administration schedules based on the trial protocol. The study includes an approximately two-year period for measuring overall survival as the primary outcome. During the trial, participants will undergo regular assessments including imaging scans to evaluate tumor response, laboratory tests, and monitoring for adverse events. Secondary outcomes include progression-free survival, objective response rate, disease control rate, duration of response, and time to tumor recurrence, observed over about one year. Safety is closely monitored until 28 days after the last treatment. The total participation time varies depending on individual outcomes and follow-up schedules.

Age: 18Years - 75YearsAll GendersPhase 3
71 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TQB6411 Injection in adults with recurrent or metastatic esophageal cancer who have not responded to prior treatment with PD-1PD-L1 inhibitors combined with platinum-based chemotherapy. This study includes both Phase Ib, focusing on safety and tolerance, and Phase II, which assesses how well the treatment works in this patient group. Participants receive TQB6411 Injection in treatment cycles lasting either 21 or 28 days. TQB6411 is an antibody-drug conjugate targeting specific proteins EGFR and c-Met involved in cancer growth. The treatment is given continuously during the study period to evaluate its effects and safety. During the trial, participants will have regular assessments including tumor measurements, blood tests, and monitoring for side effects over a period of up to 24 months. Researchers will measure outcomes such as recommended dose, adverse events, progression-free survival, response rates, and overall survival. Additional tests will evaluate drug concentration in the blood and immune responses to the treatment. Participants will be closely monitored for safety throughout the study duration.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
30 locations
E

Actively Recruiting

Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.

Age: 18Years +FEMALEPhase Not Applicable
110 locations